Addition of anti-TFPI abs shortened the LTs significantly in both the pancreatic cancer and the healthy control group, and it also reduced the variability between individuals in both groups, most evidently within the healthy group (Fig 1B). Here, TFPI is linked to familial pancreatic carcinoma.